| TITLE |
DATE |
| Idera Pharmaceuticals Announces FDA Authorization to Proceed with a Phase 2 Clinical Trial of IMO-3100 in Patients with Psoriasis |
1-Dec-2011 |
| Idera Pharmaceuticals Regains Global Rights to IMO-2055 in Oncology
from Merck KGaA |
30-Nov-2011 |
| Idera Announces Presentation on Preclinical Studies of TLR Antagonist Candidate in Models of Atherosclerosis at American Heart Association Scientific Sessions 2011 |
16-Nov-2011 |
| Idera Pharmaceuticals Presents Preclinical Data on its Gene-silencing Oligonucleotides (GSOs) at EuroTIDES 2011 Conference |
15-Nov-2011 |
| Idera Pharmaceuticals Reports Third Quarter 2011 Financial Results |
9-Nov-2011 |
| Idera Pharmaceuticals Completes $9.5 Million Financing |
4-Nov-2011 |
| Idera Pharmaceuticals Presents Preclinical Data of its Gene-silencing Oligonucleotides (GSO) at Cell Symposium on Regulatory RNAs |
11-Oct-2011 |
| Idera Pharmaceuticals Announces Jonathan Wilkin, M.D., to Join Autoimmune Disease Scientific Advisory Board |
5-Oct-2011 |
| Idera Pharmaceuticals Announces Presentation at 2nd Annual Cancer Immunotherapy Conference |
3-Oct-2011 |
| Idera Pharmaceuticals to Present at UBS 2011 Global Life Sciences
Conference |
15-Sep-2011 |
| Idera Pharmaceuticals Provides Update on Its Patent Portfolio |
9-Aug-2011 |
| Idera Pharmaceuticals Reports Second Quarter 2011 Financial Results |
5-Aug-2011 |
| Idera Reports Clinical Hold on Proposed Phase 2 Clinical Trial of
IMO-3100 |
20-Jul-2011 |
| Idera Pharmaceuticals Provides Update on IMO-2055 Clinical Development Program |
7-Jul-2011 |
| Idera Pharmaceuticals Presents Mechanism of Action Data of IMO-3100
in a Preclinical Model of Arthritis at FOCIS 2011 Annual Meeting |
23-Jun-2011 |
| Idera Pharmaceuticals to Present at Upcoming Conferences |
21-Jun-2011 |
| Idera Pharmaceuticals Presents Preclinical Data on Novel
Gene-Silencing Oligonucleotide Technology at TIDES 2011 Conference |
24-May-2011 |
| Idera Pharmaceuticals to Present at the Noble Financial Capital Markets' Seventh Annual Equity Conference |
10-May-2011 |
| Idera Pharmaceuticals Reports First Quarter 2011 Financial Results |
5-May-2011 |
| Idera Pharmaceuticals Delays Initiation of Phase 2 Clinical Trial of
IMO-2125 in Treatment-Naļve HCV Patients |
22-Apr-2011 |
| Idera Pharmaceuticals Publishes Data Demonstrating Novel
Gene-silencing Oligonucleotide (GSO) Technology |
18-Apr-2011 |
| Idera Pharmaceuticals Presents Data from a Multiple-Dose Phase 1
Clinical Trial of IMO-3100, Lead Drug Candidate for the Treatment of
Autoimmune Diseases |
4-Apr-2011 |
| Idera Pharmaceuticals Presents Data from a Phase 1 Clinical Trial of
IMO-2125 in Treatment-Naļve Genotype 1 HCV Patients atEASL 2011 |
2-Apr-2011 |
| Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2010
Financial Results |
10-Mar-2011 |
| Idera Pharmaceuticals Announces IMO-2125 Data Presentation at the
46th Annual Meeting of the European Association for the Study of the
Liver |
8-Mar-2011 |
| Idera Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference |
28-Feb-2011 |
| Idera Pharmaceuticals Presents Data on IMO-3100 in Preclinical Lupus
Model Showing Suppression of Disease Progression Parameters |
14-Feb-2011 |
| Idera Pharmaceuticals to Present at the 13th
Annual BIO CEO & Investor Conference |
7-Feb-2011 |
| Idera Pharmaceuticals Announces Preliminary Data from Phase 1 Clinical Trial of IMO-2125 in Treatment-Naļve Genotype 1 HCV Patients |
20-Dec-2010 |
| Idera Presents Preclinical Data on Dual Agonist of TLR7 and TLR8, IMO-4200, at American Society for Hematology Meeting |
6-Dec-2010 |
| Idera Pharmaceuticals Presents Preclinical Data on Mechanism of Action of TLR Antagonist Candidate in Model of Hyperlipidemia at American Heart Association Meeting |
17-Nov-2010 |
| Idera Pharmaceuticals Presents Preclinical Data from its Autoimmune Disease Program at the 74th Annual Scientific Meeting of the American College of Rheumatology |
9-Nov-2010 |
| Idera Pharmaceuticals Reports Third Quarter 2010 Financial Results
and Provides Pipeline Update |
4-Nov-2010 |
| Idera Pharmaceuticals Presents Phase 1 Data on IMO-2125 Demonstrating Induction of Broad Antiviral Immune Response in Null-Responder HCV Patients |
30-Oct-2010 |
| Idera Pharmaceuticals Announces Data Presentation of Proprietary Toll-Like Receptor 3 Agonist Compounds and Their Use as Vaccine Adjuvants |
29-Oct-2010 |
| Idera Pharmaceuticals Appoints Sudhir Agrawal as Chairman of Board of Directors and William S. Reardon as Lead Director |
29-Oct-2010 |
| Idera Pharmaceuticals Presents Phase 1 Clinical Data for IMO-3100, Lead Candidate for the Treatment of Autoimmune Diseases, and Provides Program Update |
21-Oct-2010 |
| Idera Pharmaceuticals to Present at the 17th
Annual NewsMakers in the Biotech Industry Conference |
18-Oct-2010 |
| Idera Pharmaceuticals Announces IMO-2125 Presentation at the 61st
Annual Meeting of the American Association for the Study of Liver
Diseases (AASLD) |
1-Oct-2010 |
| Idera Pharmaceuticals to Present at Upcoming Investor Conferences |
8-Sep-2010 |
| Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment |
27-Aug-2010 |
| Idera Pharmaceuticals Reports Second Quarter 2010 Financial Results and Provides Pipeline Update |
5-Aug-2010 |
| Idera Pharmaceuticals to Raise $15 Million in Registered Direct Offering |
2-Aug-2010 |
| Idera Pharmaceuticals Announces Issuance of New Patents for Its Toll-like Receptor-Targeted Compounds |
8-Jul-2010 |
| Idera Pharmaceuticals Announces the Election of Eve E. Slater, M.D.,
F.A.C.C., to Its Board of Directors |
21-Jun-2010 |
| Idera Pharmaceuticals Announces Preliminary Data from Phase 1
Clinical Trial of IMO-3100, a Toll-like Receptor Antagonist Drug
Candidate for Autoimmune and Inflammatory Diseases |
8-Jun-2010 |
| Idera Pharmaceuticals Announces Publication of Preclinical Data on
Cancer Immunotherapy with its Dual Agonist of Toll-like Receptors 7 and 8 |
4-Jun-2010 |
| Idera Pharmaceuticals to Present at Upcoming Investor Conferences |
28-May-2010 |
| Idera Pharmaceuticals to Present at Rodman & Renshaw 6th
Annual Global Healthcare Conference |
12-May-2010 |
| Idera Pharmaceuticals Reports First Quarter 2010 Financial Results
and Provides Pipeline Update |
4-May-2010 |
| Idera Pharmaceuticals Announces Positive Phase 1 Data of IMO-2125 in
Null Responder HCV Patients at EASL 2010 |
15-Apr-2010 |
| Idera Pharmaceuticals Presents Data on Anti-Atherogenic Effects of
Toll-like Receptor Antagonist in Preclinical Model of Atherosclerosis at
American Heart Association Conference |
8-Apr-2010 |
| Idera Pharmaceuticals Announces Management Appointments and Promotion |
7-Apr-2010 |
| Idera Pharmaceuticals Announces Acceptance of IMO-2125 Abstracts for
Presentation at EASL Annual Meeting |
17-Mar-2010 |
| Idera Pharmaceuticals to Present an Overview of Toll-like Receptor
Antagonist Program at 8th World Congress on
Trauma, Shock, Inflammation and Sepsis |
12-Mar-2010 |
| Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2009
Financial Results |
10-Mar-2010 |
| Idera Pharmaceuticals to Present at Roth 22nd
Annual Orange County Growth Stock Conference |
9-Mar-2010 |
| Idera Pharmaceuticals to Present at Cowen and Company 30th
Annual Health Care Conference |
3-Mar-2010 |
| Idera Pharmaceuticals Presents Mechanism of Action Data on IMO-3100,
a Novel Toll-like Receptor Antagonist for Autoimmune Diseases, at
Keystone Symposium |
23-Feb-2010 |
| Idera Pharmaceuticals Presents Preclinical Hyperlipidemia Data on a
Toll-like Receptor Antagonist at Keystone Symposium |
14-Feb-2010 |
| Idera Pharmaceuticals to Present at Annual BIO CEO & Investor Conference 2010 |
2-Feb-2010 |
| Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-3100, a
Toll-like Receptor Antagonist Intended for Autoimmune Disease Indications |
28-Jan-2010 |
| Idera Pharmaceuticals Announces the Appointment of Malcolm MacCoss,
Ph.D., to Its Board of Directors |
26-Jan-2010 |
| Idera Pharmaceuticals Announces Achievement of Clinical Milestone
Under Its Collaboration with Merck KGaA for Cancer Treatment |
19-Jan-2010 |
| Idera Pharmaceuticals Announces Positive Interim Data from Phase 1
Clinical Trial of IMO-2125 in Chronic Hepatitis C Patients |
21-Dec-2009 |
| Idera Pharmaceuticals Appoints Rahul Jasuja, Ph.D., Vice President of Corporate Development |
4-Dec-2009 |
| Idera Pharmaceuticals and Merck & Co., Inc. Extend Research Collaboration for Agonists of Toll-like Receptors as Vaccine Adjuvants |
25-Nov-2009 |
| Idera Pharmaceuticals Announces Termination of Asthma and Allergy Research Collaboration Agreement |
25-Nov-2009 |
| Idera Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides Pipeline Update |
5-Nov-2009 |
| Idera Pharmaceuticals Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009 |
3-Nov-2009 |
| Idera Pharmaceuticals Announces Issuance of Patents Covering its Novel Toll-like Receptor-Targeted Compounds and Their Use |
26-Oct-2009 |
| Idera Pharmaceuticals Presents Preclinical Data at ACR/ARHP 2009 Annual Meeting on IMO-3100, a Toll-Like Receptor Antagonist, in Combination with Enbrel(R) in Arthritis Model |
19-Oct-2009 |
| Idera Pharmaceuticals to Present at 8th Annual BIO Investor Forum |
16-Oct-2009 |
| Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-2125, a TLR9 Agonist, in Combination with Ribavirin for Chronic Hepatitis C Virus Infection |
7-Oct-2009 |
| Idera Pharmaceuticals to Present at 11th Annual Massachusetts Biotechnology Investors Forum |
1-Oct-2009 |
| Idera Pharmaceuticals Presents Final Data from Phase 2 Clinical Trial of IMO-2055 Monotherapy in Renal Cell Carcinoma |
25-Sep-2009 |
| Idera Pharmaceuticals Presents Interim Data from Phase 1b Clinical Trial of IMO-2055 in Combination with Tarceva(R) and Avastin(R) in Non-Small Cell Lung Cancer |
23-Sep-2009 |
| Idera Pharmaceuticals to Present at UBS Global Life Sciences Conference |
15-Sep-2009 |
| Idera Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference |
3-Sep-2009 |
| Idera Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides Pipeline Update |
4-Aug-2009 |
| Idera Pharmaceuticals to Present at Upcoming Investor Conferences |
31-Jul-2009 |
| Idera Pharmaceuticals Provides Update on Drug Candidate Pipeline Targeted to Toll-like Receptors |
16-Jun-2009 |
| Idera Pharmaceuticals Announces Presentations of Preclinical Data on Modulation of Toll-like Receptors 3, 7, and 9 through Antisense |
15-Jun-2009 |
| Idera Pharmaceuticals to Present at Noble Financial Capital Market's Fifth Annual Equity Conference |
1-Jun-2009 |
| Idera Pharmaceuticals to Present at BIO Business Forum and Participate in Panel at BIO 2009 |
15-May-2009 |
| Idera Pharmaceuticals Announces Presentation of Preclinical Data on IMO-3100, a Lead TLR Antagonist Drug Candidate for Autoimmune Diseases, during American Association of Immunologists Annual Meeting |
11-May-2009 |
| Idera Pharmaceuticals Reports First Quarter 2009 Financial Results |
6-May-2009 |
| Idera Pharmaceuticals Announces Issuance of Patents Claiming Novel Toll-like Receptor-Targeted Immune Modulatory Oligonucleotides and Their Use |
23-Apr-2009 |
| Idera Pharmaceuticals to Present Preclinical Data on its Agonists of Toll-Like Receptors at AACR 2009 Annual Meeting |
15-Apr-2009 |
| Idera Pharmaceuticals Reports 2008 Fourth Quarter and Full Year Financial Results |
11-Mar-2009 |
| Idera Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference |
10-Mar-2009 |
| Idera Pharmaceuticals Scientists Co-Author Paper on Preclinical Data of Investigational Cancer Vaccine |
4-Mar-2009 |
| Idera Pharmaceuticals Announces Achievement of Clinical Milestone Under its Collaboration with Merck KGaA for Cancer Treatment |
2-Feb-2009 |
| Idera Pharmaceuticals to Present at Annual BIO CEO & Investor Conference 2009 |
30-Jan-2009 |
| Idera Pharmaceuticals Announces Publication of Studies on Chemistry of Novel Antagonists for Toll-like Receptors 7 and 9 |
5-Jan-2009 |
| Massachusetts General Hospital and Idera Pharmaceuticals Receive Cooperative Research Grant from Massachusetts Life Sciences Center for Developing New Therapies for Lupus |
22-Dec-2008 |
| Idera Pharmaceuticals to Present at 10th Annual Massachusetts Biotechnology Investors Forum |
8-Dec-2008 |
| Idera Pharmaceuticals and Merck & Co., Inc. Extend Research Collaboration for Agonists of Toll-like Receptors |
20-Nov-2008 |
| Idera Pharmaceuticals Reports Third Quarter 2008 Financial Results |
6-Nov-2008 |
| Idera Pharmaceuticals to Present at Upcoming Investor Conferences |
27-Oct-2008 |
| Idera Pharmaceuticals Presents Data from Autoimmune Disease Program at 4th Annual Meeting of the Oligonucleotide Therapeutics Society |
16-Oct-2008 |
| Idera Pharmaceuticals Announces Issuance of Patents for Novel Immune Modulatory Oligonucleotides Targeting Toll-Like Receptors and their Use |
6-Oct-2008 |
| Idera Pharmaceuticals Announces Preliminary Data from Phase 2a Clinical Study of IMO-2055 Monotherapy in Renal Cell Carcinoma |
1-Oct-2008 |
| Idera Pharmaceuticals to Present at JMP Securities Healthcare Focus Conference |
30-Sep-2008 |
| Idera Pharmaceuticals to Present at UBS Global Life Sciences Conference |
17-Sep-2008 |
| Idera Pharmaceuticals Announces Milestone Payment Under Asthma and Allergy Collaboration |
2-Sep-2008 |
| Idera Pharmaceuticals Reports Second Quarter 2008 Financial Results |
4-Aug-2008 |
| Idera Pharmaceuticals to Present at Upcoming Investor Conferences |
30-Jul-2008 |
| Idera Pharmaceuticals Forms Autoimmune Disease Scientific Advisory Board |
16-Jun-2008 |
| Idera Pharmaceuticals to Present at BIO Business Forum 2008 |
13-Jun-2008 |
| Idera Pharmaceuticals Presents Preclinical Data of Toll-Like Receptor Antagonists in Models of Lung Inflammation and Psoriasis |
9-Jun-2008 |
| Idera Pharmaceuticals Reports First Quarter 2008 Financial Results |
12-May-2008 |
| Idera Pharmaceuticals Achieves Preclinical Milestone Under Collaboration with Merck & Co., Inc. |
1-May-2008 |
| Idera Pharmaceuticals Presents Data from Study of Toll-Like Receptor Antagonist in Preclinical Model of Multiple Sclerosis |
17-Apr-2008 |
| Idera Pharmaceuticals to Present Preclinical Data of its Toll-Like Receptor - Targeted Compounds at AACR Meeting |
9-Apr-2008 |
| Idera Pharmaceuticals Announces Issuance of Patents Claiming Novel Immune Modulatory Oligonucleotides Targeting Toll-Like Receptors |
8-Apr-2008 |
| Idera Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference |
13-Mar-2008 |
| Idera Pharmaceuticals Reports Financial Results for Fourth Quarter and Full Year Ended December 31, 2007 |
4-Mar-2008 |
| Idera Pharmaceuticals to Participate in Discussion Panel at SIGnificant Investment Options in Healthcare Conference |
28-Feb-2008 |
| Idera Pharmaceuticals to Participate in Therapeutic Workshop at BIO CEO & Investor Conference 2008 |
8-Feb-2008 |
| Idera Pharmaceuticals Announces Hart-Scott-Rodino Clearance for Collaboration Agreement with Merck KGaA |
6-Feb-2008 |
| Idera Pharmaceuticals to Present at Wachovia 2008 Healthcare Conference |
24-Jan-2008 |
| Idera Pharmaceuticals Announces Management Promotions |
10-Jan-2008 |
| Dr. Robert Karr Resigns from Management Position at Idera |
26-Dec-2007 |
| Idera Pharmaceuticals and Merck KGaA to Collaborate on Development of TLR9 Agonists for Treatment of Cancer |
19-Dec-2007 |
| Idera Pharmaceuticals Initiates Phase 1b Trial of IMO-2055 in Combination with Targeted Agents in Non-Small Cell Lung Cancer |
13-Dec-2007 |
| Idera Pharmaceuticals Common Stock Begins Trading on NASDAQ Global Market Today |
10-Dec-2007 |
| Idera Pharmaceuticals Common Stock Approved for Listing on NASDAQ Global Market |
26-Nov-2007 |
| Idera Pharmaceuticals to Present at Upcoming Conferences |
20-Nov-2007 |
| Idera Pharmaceuticals Appoints Louis Arcudi as Chief Financial Officer |
14-Nov-2007 |
| Idera Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2007 |
13-Nov-2007 |
| Idera Pharmaceuticals Announces Publication of Study Evaluating Synthetic Toll-like Receptor 9 Agonists |
9-Nov-2007 |
| Idera Pharmaceuticals to Participate at BIO InvestorForum 2007 |
5-Oct-2007 |
| Idera Pharmaceuticals Announces Issuance of US Patent for Novel Oligonucleotide Compositions Targeted to Toll-like Receptors |
3-Oct-2007 |
| Idera Pharmaceuticals Announces the Appointment of Hans Mueller, Ph.D., to Its Board of Directors |
27-Sep-2007 |
| Idera Pharmaceuticals Presents Preclinical Data on IMO-2125 and Other TLR9 Agonists |
17-Sep-2007 |
| Idera Pharmaceuticals Initiates Phase 1 Trial of IMO-2125 in Hepatitis C |
17-Sep-2007 |
| Idera Pharmaceuticals to Participate in Upcoming Conferences |
13-Sep-2007 |
| Idera Pharmaceuticals Presents Interim Data from Phase 1 Study Evaluating IMO-2055 in Combination with Gemcitabine and Carboplatin |
6-Sep-2007 |
| Idera Pharmaceuticals Announces Issuance of US Patent for Novel Immunostimulatory Oligonucleotide Compositions |
29-Aug-2007 |
| Idera Pharmaceuticals Announces Publication of Preclinical Data on Toll-Like Receptor 7 and 8 Agonists |
14-Aug-2007 |
| Idera Pharmaceuticals to Present at Canaccord Adams 27th Annual Global Growth Conference |
3-Aug-2007 |
| Idera Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2007 |
1-Aug-2007 |
| Idera Pharmaceuticals Announces Publication of Study of Toll-Like Receptor 9 Agonist in Combination with Avastin(R) in Preclinical Colon Cancer Model |
17-Jul-2007 |
| Idera Pharmaceuticals Presents Preclinical Data of Toll-Like Receptor Antagonists in Rheumatoid Arthritis Models |
17-Jul-2007 |
| Idera Pharmaceuticals Announces Chief Financial Officer to Leave Company Effective July 31, 2007 |
21-May-2007 |
| Idera Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2007 |
15-May-2007 |
| Idera Pharmaceuticals to Present at Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference |
10-May-2007 |
| Idera Pharmaceuticals to Present at BIO Business Forum and Participate in Toll-Like Receptor Panel at BIO 2007 |
3-May-2007 |
| Idera Pharmaceuticals Announces Presentations of Preclinical Data on New Potential Oncology Applications of its TLR9 Agonists at AACR |
18-Apr-2007 |
| Idera Pharmaceuticals to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference |
5-Apr-2007 |
| Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2006 Financial Results |
6-Mar-2007 |
| Idera Pharmaceuticals Announces Extension of Research Collaboration on Asthma and Allergy |
6-Mar-2007 |
| Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2006 Financial Results |
6-Mar-2007 |
| Idera Pharmaceuticals Appoints Dr. Alice Bexon, Vice President of Clinical Development |
21-Feb-2007 |
| Idera Pharmaceuticals Announces Issuance of US Patent for Oligonucleotide Compositions that Activate Toll-Like Receptors |
14-Feb-2007 |
| Idera Pharmaceuticals Presents Preclinical Data in Lupus Disease Models on Use of Novel Class of Antagonists for Toll-Like Receptors |
12-Feb-2007 |
| Idera Pharmaceuticals to Present at Upcoming Conferences |
5-Feb-2007 |
| Merck & Co., Inc. and Idera Pharmaceuticals Sign Collaboration Agreement Incorporating Idera's Toll-like Receptor Agonists in Merck's Vaccine Programs |
11-Dec-2006 |
| Idera Pharmaceuticals to Present BMO Capital Markets |
30-Nov-2006 |
| Idera Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2006 |
14-Nov-2006 |
| Idera Presents Preclinical Data on Novel Class of Toll-Like Receptor Antagonists |
10-Nov-2006 |
| Idera Pharmaceuticals to Present at Rodman & Renshaw 8th Annual Healthcare Conference |
1-Nov-2006 |
| Idera to Draw Down $4 Million under Existing Equity Vehicle |
24-Oct-2006 |
| Idera Pharmaceuticals Announces Issuance of a US Patent for Method of Inducing an Immune Response through Administration of Immune Modulatory Oligonucleotides |
4-Oct-2006 |
| Idera Pharmaceuticals Announces the Issuance of US Patent Claiming Compounds that Target Toll-like Receptor 9 |
13-Sep-2006 |
| Idera Pharmaceuticals to Present at Upcoming Investor Conferences |
1-Sep-2006 |
| Idera Pharmaceuticals Announces 2006 Financial Results for the Three and Six Months Ended June 30, 2006 |
15-Aug-2006 |
| Idera Pharmaceuticals Announces Formation of Oncology Clinical Advisory Board |
25-Jul-2006 |
| Idera Pharmaceuticals Announces the Granting of Patents on Immune Modulatory Compounds that Target Toll-like Receptors |
17-Jul-2006 |
| Idera to Draw Down $3.5 Million under Existing Equity Vehicle |
10-Jul-2006 |
| Idera Pharmaceuticals Announces Effectiveness of Reverse Split |
29-Jun-2006 |
| Idera Pharmaceuticals to Effect a Reverse Stock Split |
22-Jun-2006 |
| Idera Presents Preclinical Data at ASCO on Agonists to Toll-like Receptor 9 in Combination with Chemotherapeutic and Targeted Therapies in Lung Cancer Models |
5-Jun-2006 |
| Idera Pharmaceuticals Broadens Toll-like Receptor Programs |
15-May-2006 |
| Idera Pharmaceuticals Management to Make Presentations at BIO 2006 |
6-Apr-2006 |
| IDERA PHARMACEUTICALS SECURES $19.5 MILLION IN FUNDING |
27-Mar-2006 |
| IDERA PHARMACEUTICALS TO PARTICIPATE IN FOCUS SESSION AT BIO CEO & INVESTOR CONFERENCE |
13-Feb-2006 |
 |
